Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9463MR)

This product GTTS-WQ9463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9463MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ959MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ5854MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ9603MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ1217MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ12567MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ11548MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ4204MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW